FDA Approves Vidaza Label Expansion
"We are very encouraged by the Vidaza data from the AZA-001 trial. This trial showed, for the first time, a drug can extend survival for MDS patients," said John Huber, Executive Director of the Aplastic Anemia and MDS International Foundation. "We are excited to see that in this trial Vidaza also reduced the need for blood transfusions."
MDS occur when the bone marrow stem cells malfunction. This results in the production of too many defective blood cells and not enough normal cells. Diagnosis is made through blood tests and a bone marrow biopsy. Once diagnosed, treatment and evaluation should occur under the care of a hematologist or hematologist/oncologist. There are many subtypes of MDS classified according to how the disease manifests itself in the blood and marrow of the patient. Treatments include blood transfusions, growth factors, chemotherapy and bone marrow transplant.
About the Aplastic Anemia and MDS International Foundation
Founded in 1983, the Aplastic Anemia & MDS International Foundation is dedicated to serving as a resource for patient assistance, advocacy, and support. AA&MDSIF provides patients and their families with support, as well as the latest medical information. AA&MDSIF also funds research to find cures for aplastic anemia, myelodysplastic syndromes (MDS), paroxysmal nocturnal hemogloburina (PNH), and other bone marrow failure diseases. Educational and support resources are free to patients and families, the media and the general public at http://www.aamds.org/.
Source: John Huber
Aplastic Anemia & MDS International Foundation
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:
Huber, John. "FDA Approves Vidaza Label Expansion." Medical News Today. MediLexicon, Intl., 22 Aug. 2008. Web.
23 Mar. 2017. <http://www.medicalnewstoday.com/releases/119043.php>
Huber, J. (2008, August 22). "FDA Approves Vidaza Label Expansion." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
Contact our news editors
For any corrections of factual information, or to contact our editorial team, please see our contact page.
Copyright Medical News Today: Excluding email/sharing services explicitly offered on this website, material published on Medical News Today may not be reproduced, or distributed without the prior written permission of Medilexicon International Ltd. Please contact us for further details.